RenovoRx, Inc. aktie
RNXT
Pre-market$0.9105-0.0102 (-1.11%)
Pre-Market:$0.9189+0.01 (+0.92%)
Laddar diagram...
RenovoRx, Inc.
Market Cap
$41,062,760
Öppning0.9459
Högsta0.9700
Lägsta0.9100
Volym237.44k
P/EN/A
Börsvärde41.06M
52 veckors högsta1.4500
52 veckors lägsta0.7010
Genomsnittlig volym374.34k
UtdelningN/A
BetaN/A
EPS-0.3300
Om RenovoRx, Inc. aktie
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Företagsinformation
Börs: NasdaqCM (NCM)
Sektor: Sundhed
Industri: Bioteknologi
Adress:
2570 West El Camino Real
94040 Mountain View, United States
94040 Mountain View, United States
Telefon: + 650 284 4433
Hemsida: https://renovorx.com
Analytikernas aktierekommendationer
Denna översikt ger en snabb insikt i hur analytiker bedömer aktiens potential baserat på deras senaste analyser och kursmål.
Lägsta kursmål
3.00
↑ 229.5%
Genomsnittligt kursmål
7.03
↑ 672.1%
Median kursmål
5.56
↑ 510.7%
Högsta kursmål
14.00
↑ 1437.6%